HUNTSVILLE — Discovery Life Sciences has announced the launch of its proteomic services division. With the announcement, the HudsonAlpha-based company is accepting samples from pharmaceutical and biotech companies, government, and nonprofit and academic research centers.
“We are very excited to open our doors to researchers and scientists worldwide and provide them access to Discovery’s highly-scaled, multi-omic services to advance their biomarker discovery, clinical development, and large-scale research programs,” said Michael Pisano, Discovery’s executive vice president of Proteomics. “Our proteomic experts carefully designed, built, and optimized a comprehensive, platform-agnostic suite of leading-edge proteomic and proteo-genomic technologies to support all biomarker strategies, large-scale population studies, and biobank characterization projects.”
Proteomics is the study of the structure and function of proteins, including the way they work and interact with each other inside cells.
Discovery’s division includes exploratory and targeted proteomics using the Seer Proteograph Product Suite, SCIEX LC-MS/MS systems, Olink Proximity Extension Assay, and Luminex xMAP platforms.
The Seer PGPS adds unbiased, deep, rapid proteomics studies at scale to any lab.
Discovery said its proteomic service laboratories are integrated with its genomic service laboratories and expansive global commercial biorepository of hyper-annotated biospecimens.
This creates a single source for large-scale population studies, biobank characterization, and multi-omic biomarker analysis to support drug and diagnostic development
As a part of its biomarker services expansion strategy, Discovery signed a multi-year agreement in January with Seer, a life science company commercializing a disruptive new platform for proteomics; and SCIEX, a global leader in life science analytical technologies, to form a first-of-its-kind Proteogenomics Consortium for large-scale plasma proteomic studies.
“The Proteogenomics Consortium strategically unites these highly advanced plasma proteomic technologies with our world-leading expertise in short- and long-read genomics to add deep, unbiased proteomics data more easily to discovery, translational, and clinical studies, as well as large-scale population research programs,” said Glenn Bilawsky, CEO at Discovery. “In addition, the PGC also enables the creation of new diagnostic tools for cancer, neurodegenerative, inflammatory, infectious diseases, and other therapeutic areas.”
In September, Discovery announced it was the largest certified commercial service provider for the Olink PEA platform in the Americas. Olink’s PEA is a unique immuno-PCR technology that solves the dynamic range issue that has hindered plasma proteomics for decades, allowing for the detection and quantitation of low abundant proteins in plasma at scale.
Discovery will also implement complementary multiplex immunoassay platforms, including xMAPÂ technology from Luminex, enabling customizable protein and nucleic acid-based multiplex assays.
Discovery offers a wide range of services, including genomics, proteomics, pathology, and cell biology.
Accompanying its extensive service portfolio, Discovery has the world’s largest commercial biorepository, offering partners a single chain of custody to accelerate clinical research and development. Discovery’s integrated, multi-omic workflow enables clients to gain deeper insights while conserving precious samples.
Don’t miss out!  Subscribe to our email newsletter to have all our smart stories delivered to your inbox.
